Galapagos has announced its intention to wind down its cell therapy business, following a comprehensive review of strategic alternatives, including a potential divestiture. The move follows similar ones by Novo Nordisk and Takeda, which recently announced the decision to discontinue its cell… Read More
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL). To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has… Read More
Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More
